Abstract
We know that within the complex mammalian gut is any number of metabolic biomes. The gut has been sometimes called the “second brain” within the “gut-brain axis”. A more informative term would be the gut-brain metabolic interactome, which is coined here to underscore the relationship between the digestive system and cognitive function or dysfunction as the case may be. Co-metabolism between the host and the intestinal microbiota is essential for life’s processes. How diet, lifestyle, antibiotics and other factors shape the gut microbiome constitutes a rapidly growing area of research. Conversely, the gut microbiome also affects mammalian systems. Metabolites of the gut-brain axis are potential targets for treatment and drug design since the interaction or biochemical interplay results in net metabolite production or end-products with either positive or negative effects on human health. This review explores the gut-brain metabolic interactome, with particular emphasis on drug design and treatment strategies and how commensal bacteria or their disruption lead to dysbiosis and the effect this has on neurochemistry. Increasing data indicate that the intestinal microbiome can affect neurobiology, from mental and even behavioral health to memory, depression, mood, anxiety, obesity, cravings and even the creation and maintenance of the blood brain barrier.
Keywords: Antibiotics, Microbiota, Neurotransmitters, Gut Brain axis, Metabolomics, Fecal Material Transplant, Signaling, Metabolic Crosstalk, Trimethylamine, Trimethylamine N-Oxide, Carnitine.
CNS & Neurological Disorders - Drug Targets
Title:The Co-Metabolism within the Gut-Brain Metabolic Interaction: Potential Targets for Drug Treatment and Design
Volume: 15 Issue: 2
Author(s): Mark Obrenovich, Rudolf Flückiger, Lorraine Sykes and Curtis Donskey
Affiliation:
Keywords: Antibiotics, Microbiota, Neurotransmitters, Gut Brain axis, Metabolomics, Fecal Material Transplant, Signaling, Metabolic Crosstalk, Trimethylamine, Trimethylamine N-Oxide, Carnitine.
Abstract: We know that within the complex mammalian gut is any number of metabolic biomes. The gut has been sometimes called the “second brain” within the “gut-brain axis”. A more informative term would be the gut-brain metabolic interactome, which is coined here to underscore the relationship between the digestive system and cognitive function or dysfunction as the case may be. Co-metabolism between the host and the intestinal microbiota is essential for life’s processes. How diet, lifestyle, antibiotics and other factors shape the gut microbiome constitutes a rapidly growing area of research. Conversely, the gut microbiome also affects mammalian systems. Metabolites of the gut-brain axis are potential targets for treatment and drug design since the interaction or biochemical interplay results in net metabolite production or end-products with either positive or negative effects on human health. This review explores the gut-brain metabolic interactome, with particular emphasis on drug design and treatment strategies and how commensal bacteria or their disruption lead to dysbiosis and the effect this has on neurochemistry. Increasing data indicate that the intestinal microbiome can affect neurobiology, from mental and even behavioral health to memory, depression, mood, anxiety, obesity, cravings and even the creation and maintenance of the blood brain barrier.
Export Options
About this article
Cite this article as:
Obrenovich Mark, Flückiger Rudolf, Sykes Lorraine and Donskey Curtis, The Co-Metabolism within the Gut-Brain Metabolic Interaction: Potential Targets for Drug Treatment and Design, CNS & Neurological Disorders - Drug Targets 2016; 15 (2) . https://dx.doi.org/10.2174/1871527315666160202123107
DOI https://dx.doi.org/10.2174/1871527315666160202123107 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pulmonary Embolism Response Team (PERT) - A New Paradigm for the Treatment
of Pulmonary Embolism
Current Pharmaceutical Design Role of Molecular Analysis After Autopsy Negative Sudden Death in the Young
Current Pediatric Reviews Nanomedical Strategies for Targeting Skin Microbiomes
Current Drug Metabolism The Escalating Challenge of Vancomycin Resistance in Staphylococcus aureus
Current Drug Targets - Infectious Disorders Chest Pain in Children
Current Pediatric Reviews Tandem Multicomponent Reactions Toward the Design and Synthesis of Novel Antibacterial and Cytotoxic Motifs
Current Medicinal Chemistry Hybrid Drugs as Potential Combatants Against Drug-Resistant Microbes: A Review
Current Topics in Medicinal Chemistry The Role of Universal Stress Proteins in Bacterial Infections
Current Medicinal Chemistry Total Synthesis of ME1036 Starting from Readily Available Inexpensive Materials
Letters in Organic Chemistry Neuromuscular Disorders in Left Ventricular Hypertrabeculation/Noncompaction
Current Pharmaceutical Design Liposome-Nanogel Structures for Future Pharmaceutical Applications
Current Pharmaceutical Design New Imaging Tracers for the Infected Diabetic Foot (Nuclear and Optical Imaging)
Current Pharmaceutical Design Association of Pharmacokinetic and Pharmacodynamic Aspects of Linezolid with Infection Outcome
Current Drug Metabolism Natural Products Towards the Discovery of Potential Future Antithrombotic Drugs
Current Pharmaceutical Design Susceptibility of Intracellular Coxiella burnetii to Antimicrobial Peptides in Mouse Fibroblast Cells
Protein & Peptide Letters Bacterial Infection Probes and Imaging Strategies in Clinical Nuclear Medicine and Preclinical Molecular Imaging
Current Topics in Medicinal Chemistry Contrast Enhanced Sonography for Diagnosis of (Peri-) Splenic Pathology
Current Medical Imaging Prevention of Microbial Communities: Novel Approaches Based Natural Products
Current Pharmaceutical Biotechnology Bedside Lung Ultrasound in the Care of the Critically Ill
Current Respiratory Medicine Reviews Cyclic Peptides that Govern Signal Transduction Pathways: From Prokaryotes to Multi-Cellular Organisms
Current Topics in Medicinal Chemistry